The aim of the research: identify combinations of genetic and neurohumoral factors that influence the development of true resistance to antihypertensive therapy (AHT) in patients with concomitant obesity (OB).
Materials and Methods. The study included 200 patients aged 45–55 with uncontrolled hypertension and obesity. Treatment was prescribed in accordance with the European Guidelines 2018. Thiazide-like diuretics were additionally prescribed to those patients who did not reach the target blood pressure (BP) level after 3 months of dual therapy. Resistant hypertension was diagnosed in 48 patients who had an uncontrolled course of hypertension at the optimal doses of three antihypertensive drugs during the next month of their reception, while true resistance was found in 21 patients. The effectiveness of comprehensive treatment was evaluated after 6 months.
Results. The application of the logistic regression method at the stage of initial examination of patients showed that the early predictors of the formation of truly resistant hypertension in obese patients are CIMT, HOMA index and genetic polymorphism IRS-1.
After treatment, the model of truly resistant hypertension in patients with obesity included indicators that influenced its formation at the pre-treatment stage, as well as the new ones: adiponectin, waist circumference and genetic polymorphism ADIPOQ.
Conclusions. Genetic markers, insulin resistance, and vascular wall status play a leading role in the development of true resistance to AHT in obese patients. It is established that the main determinants of the formation of true resistance to AHT in patients with this comorbidity are IRS-1 polymorphism, HOMA index and CIMT.
2. Kotsis V, Jordan J, Micic D, et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High‐risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. J. Hypertens. 2018;36:1427‐40. DOI: 10.1097/HJH.0000000000001730.
3. Leggio M, Lombardi M, Caldarone E, Severi P, D'Emidio S, Armeni M, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. J. Hypertens. Res. 2017;40(12):947-63.
4. Mishchenko LA, Kupchynska OH, Matova OO, Serbeniuk KI, Hulkevych OV, Radchenko VV. Osoblyvosti urazhennia orhaniv-mishenei u patsiientiv iz rezystentnoiu arterialnoiu hipertenziieiu. Arterialna hipertenziia. 2020;13(2-3):66-74. DOI:10.22141/2224-1485.13.2-3.2020.205339
5. Mishchenko LA, Matova OO, Sheremet M Yu, Serbeniuk KI,. Kuchmenko OB. Aktyvnist systemnoho zapalennia nyzkoi hradatsii v patsiientiv z rezystentnoiu arterialnoiu hipertenziieiu. Arterialna hipertenziia. 2018;5:15-21. DOI: http://doi.org/10.31928/1608-635X-2018.5.1521
6. Muxfeldt ES, Chedier B, Rodrigues CIS. Resistant and refractory hypertension: two sides of the same disease? J. Bras. Nefrol. 2019 Apr-Jun; 41(2):266-74.
7. Baranov VS, Baranova EV. Genom cheloveka, epigenetika mnogofaktornyih bolezney i personifitsirovannaya meditsina [Human genome, epigenetics of complex diseases, and personalized medicine]. Biosphere. 2012;4(1):76-85. (RU).
8. Puzyirev VP. Meditsinskaya patogenetika [Medical pathogenetics]. Vavilov Journal of Genetics and Breeding. 2014;18(1):7-21. (RU).
9. Delles C, Padmanabhan S. Genetics and Hypertension: Is It Time to Change My Practice? Canadian Journal of Cardiology. 2012;28:296–304.
10. Alpert MA, Omran J, Bostick BP. Effects of obesity on cardiovascular hemodynamics, cardiac morphology, and ventricular function. J. Curr. Obes. Rep. 2016;5(4):424-34.
11. Jiang SZ, Lu W, Zong XF, Ruan HY, Liu Y. Obesity and hypertension (Review). Experimental and Therapeutic Medicine. 2016 Oct;12(4):2395-9. DOI: https://doi.org/10.3892/etm.2016.3667
12. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. J. Gland. Surg. 2020 Feb; 9(1): 80-93. DOI: 10.21037/gs.2019.12.03
13. Psarova, VH. Molecular genetic and neurohumoral mechanisms of cardiovascular remodeling and their correction in patients with essential hypertension with concomitant obesity [dissertation manuscript]. Kharkiv; 2020. 393 p.
14. Ivanova OV, Rogoza AN, Balahonova TV, Sobole¬va GN, Atkov OYu, Karpov YuA. Opredelenie chuvstvitelnosti plechevoy arterii k napryazheniyu sdviga na endoteliy, kak metod otsenki sostoyaniya endoteliy zavisimoy vazodilatatsii s pomoschyu ultrazvuka vyisokogo razresheniya u bolnyih s arterialnoy gipertoniey [Sensitivity of endothelium of the brachial artery to shear stress-method to evaluate endothelial function in patients with hypertension]. Kardiologiya. 1998; 3:37-42 (RU).
15. Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. J. Circ. Res. 2019 Mar 29;124(7):1061-70. DOI:10.1161/CIRCRESAHA.118.312156.
16. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-115.
This work is licensed under a Creative Commons Attribution 4.0 International License.